Clinical trials using GDF8 inhibitors have covered patients with various muscular dystrophies, idiopathic inflammatory myopathies, cancer cachexia, chronic obstructive pulmonary disease (COPD), and aging/sarcopenia (61). This evidence concerns the gene MSTN and idiopathic inflammatory myopathy.